NCT02577185View on ClinicalTrials.gov

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Psoriasis Vulgaris

Interventions

DRUG

Botulinum Toxin Type A

DRUG

Sodium chloride 9 mg/ml

Trial Locations (2)

2900

Hud- og allergiafdeling, Gentofte Hospital, Gentofte Municipality

8000

Hud- og Kønssygdomme, Aarhus Universitetshospital, Aarhus

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LEO Pharma

INDUSTRY